Literature DB >> 25187913

[Radiotherapy of bulky disease after completion of chemotherapy improves immune outcome of elderly patients with aggressive B-cell lymphoma. ].

Stefan Kubicka.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25187913     DOI： 10.1007/s00066-014-0701-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.

Authors:  A J Swerdlow; J A Barber; G V Hudson; D Cunningham; R K Gupta; B W Hancock; A Horwich; T A Lister; D C Linch
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Authors:  Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Mohren; Eva Lengfelder; Marcel Reiser; Christina Nickenig; Michael Clemens; Norma Peter; Carsten Bokemeyer; Hartmut Eimermacher; Anthony Ho; Martin Hoffmann; Roland Mertelsmann; Lorenz Trümper; Leopold Balleisen; Ruediger Liersch; Bernd Metzner; Frank Hartmann; Bertram Glass; Viola Poeschel; Norbert Schmitz; Christian Ruebe; Alfred C Feller; Markus Loeffler
Journal:  Lancet Oncol       Date:  2008-01-15       Impact factor: 41.316

3.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

Authors:  Malik E Juweid; Gregory A Wiseman; Julie M Vose; Justine M Ritchie; Yusuf Menda; James E Wooldridge; Felix M Mottaghy; Eric M Rohren; Norbert M Blumstein; Alan Stolpen; Brian K Link; Sven N Reske; Michael M Graham; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

4.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

5.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.

Authors:  Andrea K Ng; M Patricia Bernardo; Edie Weller; Kendall H Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Jonathan Friedberg; George P Canellos; Peter M Mauch
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

6.  Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation.

Authors:  Shira L Galper; James B Yu; Peter M Mauch; Jon F Strasser; Barbara Silver; Ann Lacasce; Karen J Marcus; Mary Ann Stevenson; Ming Hui Chen; Andrea K Ng
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

7.  Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.

Authors:  Andrea K Ng; M V Patricia Bernardo; Edie Weller; Kendall Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Mary Ann Stevenson; Jonathan W Friedberg; Peter M Mauch
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  T P Miller; S Dahlberg; J R Cassady; D J Adelstein; C M Spier; T M Grogan; M LeBlanc; S Carlin; E Chase; R I Fisher
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

9.  Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.

Authors:  Gerhard Held; Niels Murawski; Marita Ziepert; Jochen Fleckenstein; Viola Pöschel; Carsten Zwick; Jörg Bittenbring; Mathias Hänel; Sibylla Wilhelm; Jörg Schubert; Norbert Schmitz; Markus Löffler; Christian Rübe; Michael Pfreundschuh
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.